RecruitingNot ApplicableNCT07254988
Gut Peptides and Bone Remodeling in Children With Neuromuscular Disorders
Sponsor
University of Copenhagen
Enrollment
8 participants
Start Date
Mar 24, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Both GIP and GLP-2 reduce bone resorption (measured as CTX) in healthy adult individuals. In this study, we will investigate whether GIP and GLP-2 reduce CTX in children with spinal muscular atrophy, duchenne muscular dystrophy, or cerebral palsy.
Eligibility
Min Age: 10 YearsMax Age: 17 Years
Inclusion Criteria1
- \- Diagnosis with Cerebral palsy (CP), Duchenne muscular dystrophy (DMD) or Spinal muscular atrophy (SMA) resulting in the need of a wheelchair
Exclusion Criteria5
- Use of anti-resorptive medication
- Confounding illnesses
- Pregnancy
- Allergy towards the components given on the test days
- Hgb<6.5 mmol/L
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERMeal test
Ingestion of an oral liquid meal (nutridrink), 3.3 mL/kg body weight.
OTHERGIP + GLP-2
Subcutaneous GIP + GLP-2 injection (1 mL containing 100 microgram GIP + 1 mL containing 400 microgram GLP-2).
OTHERPlacebo
Subcutaneous saline injection (2 mL isotonic saline).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07254988
Related Trials
Constraint-induced Movement Therapy Combined With Functional Electrical Stimulation in Children With Cerebral Palsy
NCT075874761 location
Speech Production Enhancement Using Augmentative Communication for Kids
NCT071730491 location
Childhood Toxin Perception Survey
NCT073772011 location
Assessing Intellectual and Motor Outcomes in High-risk Infants
NCT068575394 locations
Complex Rehabilitation Technology Enabled Physical Activity for Children With Motor Delays Via Telehealth in Natural Environments
NCT072527131 location